Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by Mole101on Jul 16, 2021 4:33pm
108 Views
Post# 33561238

RE:Current share price.

RE:Current share price.

 


I would have to agree with you garygp..but manipulation is taking place at the moment RBC is on the sale side on buches of 44 k from .215 to .235 and not necessarily to sale but to overweight The ask side and Annon is pushing down on the ask too , on the other side Leede and Fifelity are happily buying everyday ..RC mention some time ago that this game has been played for years and now it's not different .The question is how long will they bring it ?

quote=garygp]Just thinking out loud, but at 18.5 cents and anything lower during the summer, I believe this could be a real opportunity for both new and current shareholders to reposition themselves and add to current holdings during the summer doldrums.

Seems to me that here and lower is a gift.[/quote]
 

<< Previous
Bullboard Posts
Next >>